Setmelanotide, an MC4R agonist that activates MC4R pathway signaling [28], is an approved treatment option in the United States and European Union for chronic weight management and control of hunger in adult and pediatric patients aged 6 years and older with syndromic obesity due to BBS [29, 30]. The gene discussed is MC4R; the disease is obesity due to melanocortin 4 receptor deficiency.